First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study

Details 詳細情報について

• CRID

  1360292619132915456

• DOI

  10.1038/bjc.2013.721

• ISSN

  15321827

  00070920

• Web Site

  http://www.nature.com/articles/bjc2013721.pdf

  http://www.nature.com/articles/bjc2013721

• Data Source

  • Crossref